Investing.com - Coya Therapeutics (NASDAQ: COYA) reported fourth quarter EPS of $0.14, $0.12 worse than the analyst estimate of $0.26. Revenue for the quarter came in at $7.5M versus the consensus estimate of $7.50M.
Coya Therapeutics's stock price closed at $9.86. It is up 41.26% in the last 3 months and up 145.79% in the last 12 months.
Coya Therapeutics saw positive EPS revisions and negative EPS revisions in the last 90 days. See Coya Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Coya Therapeutics's Financial Health score is "fair performance".
Check out Coya Therapeutics's recent earnings performance, and Coya Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar